Ayodeji A. Asuni

Ayodeji A. Asuni

Auto-generated profile, based on publicly available information

Ayodeji A. Asuni

Preclinical Fluid Biomarkers and Occupancy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Neurochemistry International
Verified
Journal Article
Closed access
AAAyodeji A. Asuni
Ayodeji A. Asuni
MGMaitea Guridi
Maitea Guridi
SSSandrine Sanchez
Sandrine Sanchez
MSMartin Sadowski
Martin Sadowski

22 March 2010 in Biochemical Society Transactions
Verified
Journal Article
Closed access
PDF file
AAAyodeji A. Asuni
Ayodeji A. Asuni
VPV. Hugh Perry
V. Hugh Perry
VOVincent O'Connor
Vincent O'Connor
Hyperphosphorylation of the microtubule-associated protein tau is a significant determinant in AD (Alzheimer's disease), where it is associated with disrupted axonal transport and probably causes synaptic dysfunction. Although less well studied, hyperphosphorylation has been observed in prion disease. We have investigated the expression of hyperphosphorylated tau in the hippocampus of mice infected with the ME7 prion agent. In ME7-infected animals, there is a selective loss of CA1 synapse, first discernable at 13 weeks of disease. There is a potential that dysfunctional axonal transport contributes to this synaptopathy. Thus investigating hyperphosphorylated tau that is dysfunctional in AD could illuminate whether and how they are significant in prion disease. We observed no differences in the levels of phosphorylated tau (using MC1, PHF-1 and CP13 antibodies) in detergent-soluble and detergent-insoluble fractions extracted from ME7- and NBH- (normal brain homogenate) treated animals across disease. In contrast, we observed an increase in phospho-tau staining for several epitopes using immunohistochemistry in ME7-infected hippocampal sections. Although the changes were not of the magnitude seen in AD tissue, clear differences for several phospho-tau species were seen in the CA1 and CA3 of ME7-treated animals (pSer199−202>pSer214>PHF-1 antibody). Temporally, these changes were restricted to animals at 20 weeks and none of the disease-related staining was associated with the axons or dendrites that hold CA1 synapses. These findings suggest that phosphorylation of tau at the epitopes examined does not underpin the early synaptic dysfunction. These data suggest that the changes in tau phosphorylation recorded here and observed by others relate to end-stage prion pathology when early dysfunctions have progressed to overt neuronal loss.

1 February 2010 in Neuroscience
Verified
Journal Article
Closed access
AAA.A. Asuni
A.A. Asuni
KHK. Hilton
K. Hilton
ZSZ. Siskova
Z. Siskova
KLK. Lunnon
K. Lunnon
RRR. Reynolds
R. Reynolds
VOV. O'COnnor
V. O'COnnor

28 January 2013 in Neuroscience Letters
Verified
Journal Article
Closed access
AAAyodeji A. Asuni
Ayodeji A. Asuni
JPJoanna E. Pankiewicz
Joanna E. Pankiewicz
MSMartin Sadowski
Martin Sadowski

15 July 2019 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
JBJoakim Bastrup
Joakim Bastrup
SBSvend Birkelund
Svend Birkelund
AAAyodeji A. Asuni
Ayodeji A. Asuni
CVChristiane Volbracht
Christiane Volbracht
Allan StensballeAllan Stensballe
Allan Stensballe

30 December 2022 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
STStéphanie G. Trouche
Stéphanie G. Trouche
ABAllal Boutajangout
Allal Boutajangout
AAAyodeji Asuni
Ayodeji Asuni
PFPascaline Fontés
Pascaline Fontés
ESEinar M. Sigurdsson
Einar M. Sigurdsson
NMNadine Mestre-Francés
Nadine Mestre-Francés